Replies to post #203138 on Biotech Values

[DewDiligence]

MNTA ‘ReadMeFirst’ updated for 2Q16 results and other info:

#msg-124349097

[DewDiligence]

MNTA closes +11% on positive news from USPTO wrt 40mg Copaxone:

#msg-124747494
#msg-124748552

In short, two of TEVA’s three 40mg-Copaxone patents at issue in the IPR have been invalidated, and we’re still waiting for news from the PTO on the third (very similar) patent.

For background info on the 40mg-Copaxone patent case in US District Court (which is separate from the IPR), please see #msg-124628031.